2022 Society of Gynecologic Oncology (SGO)

DFCI Faculty share highlights from the Society of Gynecologic Oncology Annual Meeting on Women's Cancers held on March 18-21, 2022, in Phoenix, AZ and online.

Combination Therapy Produces Encouraging Results in Patients with Gynecologic Cancers with Distinct Genetic Mutations

A two-drug therapy that sets certain cancer cells up for failure and then finishes them off showed encouraging activity in a clinical trial of patients with gynecologic cancers that harbor mutations in a key gene, Dana-Farber investigators ...

Conjugate Therapy Produces Remissions in One-Third of Patients with Drug-Resistant Ovarian Cancer, Study Results Show

In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel “conjugate” therapy produced a substantially better response than standard treatments. Results from this study were ...

Ursula Matulonis, MD Shares Results of the SORAYA Study

Ursula Matulonis, MD presented results of the SORAYA study at the 2022 Society for Gynecologic Oncology Annual Meeting.
Ursula Matulonis, MD

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Institute Physician
Professor of Medicine, Harvard Medical School

Drug Combination Shows Effectiveness in Patients with Recurrent ER-Positive Endometrial Cancer

A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer. Results from this trial ...

Panos Konstantinopoulos, MD, PhD Shares Results of a Phase 2 Endometrial Cancer Study at 2022 SGO

Panos Konstantinopoulos, MD, PhD shares results of a phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or persistent endometrial cancer at the 2022 Society for Gynecologic Oncology Annual Meeting.